Amgen Inc. (AMGN) stock prices updated...
 

Amgen Inc. stock price, AMGN

Amgen Inc. stock chart:



Amgen Inc. close price: 173.14

Stock price forecast:

DOWN TO -14.65%
Target: 147.78

Total forecasts: 90
Reached: 63 (70.00%)

Total Win: 380.50 (259.83%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90916470.33%395.222.97%4,456.94-217.84-4.89%177.381.27%
3031412.90%7.170.15%4,456.94-217.84-4.89%-210.67-4.15%
141500.00%0.000.00%2,545.43-51.67-2.03%-51.67-2.03%
7800.00%0.000.00%1,372.77-12.35-0.90%-12.35-0.90%

Showing 1-10 of 478 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-02-21173.29147.50000-00-00
2017-02-20173.29146.370000-00-00
2017-02-19173.29147.220000-00-00
2017-02-18173.29146.110000-00-00
2017-02-17172.11145.760000-00-00
2017-02-16171.79145.040000-00-00
2017-02-15168.05147.030000-00-00
2017-02-14167.66147.730000-00-00
2017-02-13167.89147.260000-00-00
2017-02-12167.89147.040000-00-00

Amgen Inc. latest news:


  • 02/14/2017 14:47:05

    George Soros picks up Goldman Sachs, dumps Nvidia

    George Soros's hedge fund Soros Fund Management made a lot of changes to his portfolio in the fourth quarter, dumping positions in many companies and initiating positions in Goldman Sachs Group Inc. and Pandora Media Inc. . Soros decreased positions in Abbott Labs , Amazon.com Inc. , eBay Inc. , Netflix Inc. , and VMware Inc. . Soros also dumped positions in Activision Blizzard Inc. , Amgen Inc. , Barrick Gold Corp. , Coca-Cola Co. and Nvidia Corp. .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 02/08/2017 14:49:37

    Federal appeals court decision will keep Regeneron/Sanofi drug at center of patent dispute on market, for now

    A federal appeals court temporarily stopped another judge's decision that would have forced Regeneron and Sanofi (SNY) to stop selling cholesterol drug Praluent. The Tuesday decision, though expected, "means that Praluent will not come off the market by Feb. 21," and could even stay on the market through the rest of the year, said Evercore ISI analyst Mark Schoenebaum. The previous judge's decision in favor of Amgen Inc. (AMGN) was a for Amgen (AMGN), and sent its shares up on Jan. 7, the day the decision...

  • 02/02/2017 16:21:54

    BRIEF-Amgen CEO expects to see U.S. tax reform

    * Amgen CEO says international expansion important element of long-term growth

  • 02/02/2017 15:03:49

    Amgen fourth quarter profit tops Street view, but 2017 outlook light

    (Reuters) - Amgen Inc on Thursday posted a higher-than-expected fourth-quarter profit, helped by a jump in sales of its Enbrel rheumatoid arthritis drug, but it issued a 2017 sales and earnings forecast range below current Wall Street estimates.

  • 01/05/2017 17:09:19

    U.S. Judge Blocks Sanofi and Regeneron From Selling Cholesterol Drug

    A federal judge on Thursday blocked Sanofi SA and Regeneron Pharmaceuticals Inc from selling their cholesterol drug Praluent, a victory for Amgen Inc, which had accused them of infringing its patents.

  • 01/05/2017 16:09:50

    Amgen shares soar as judge blocks sales of Regeneron drug

    Shares of Regeneron Pharmaceuticals Inc. were halted in the extended session Thursday while shares of Amgen Inc. rallied after a federal judge said Regenron had to pull its competing cholestrol drug off the market as a penalty in a patent lawsuit. Regeneron shares were halted at $376.61, down 1.1% after hours, while shares of Amgen jumped 4.6% to $160. On Thursday, a federal judge blocked sales of Regeneron's cholesterol treatment Praluent, stating that "irreparable harm" had been done to Amgen's Repatha. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/29/2016 14:47:33

    Arrowhead Pharma shares plummet 60% on discontinued drug development

    Arrowhead Pharmaceuticals Corp. shares plummeted in the extended session Tuesday after the drug developer said it was discontinuing the development of some drug candidates and refocusing resources. Arrowhead shares dropped 60% to $1.77 after hours. The company said it would no longer pursue the development of three hepatitis treatments that use its "EX1" delivery vehicle because of substantial delays foreseen in regulatory approval. Arrowhead also said it would trim its workforce by 30%. Arrowhead said it would focus on hepatitis B treatments and others, especially those where the company is partnered with biotech giant Amgen Inc. .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Amicus Therapeutics, Inc.FOLD | Amkor Technology, Inc.AMKR | Amphastar Pharmaceuticals, Inc.AMPH | Amsurg Corp.AMSG | Amsurg Corp.AMSGP | Amtech Systems, Inc.ASYS | AmTrust Financial Services, Inc.AFSI-3.22% | Amyris, Inc.AMRS | Anacor Pharmaceuticals, Inc.ANAC | ANADIGICS, Inc.ANAD |